THE RISK OF VENOUS THROMBOEMBOLISM IN CHILDREN CARRYING PROTHROMBOTIC POLYMORPHISMS

Genetic aspects of venous thromboembolism (VTE) in children are still not well recognized. The aim of this study was to evaluate the impact of 8 prothromboticpolymorphisms on the risk of VTE in children. 43 patients aged 0-18 years with objectively diagnosed VTE were included. The control group consisted of 54 apparently healthy volunteers aged 14-30 years. It was found that minor alleles of MTHFR C677T and ITGB3 L33P do increase the risk of VTE in children (odds ratio OR 1.41,95% CI 0,69-2,89, p = 0.347 and OR 1.28, 95 0,65-2,51% CI; p = 0.469, respectively), while FV Leiden mutation (OR 1.04, 95% Cl 0,26-4,17; p = 0,951), FGB beta -455 G > A (OR 0.93, 95% CI 0,47-1,85; p = 0.842) and ITGA2 F224F C807T (OR 1.03, 95% CI 0,52-2,03; p = 0.943) had no significant effect. Variants of PAI-1 -675 (5G del 1G) OR 0.73, 95% CI 0.39-1.37, p = 0.328) and FVII R353Q did not show to increase the risk of VTE. Odds ratio for the development of VTE in FVII R353Q Q-allele carriers was 0.39 (95% CI 0.16-0.93; p = 0.034). In our study we did not observeany case of FII G20210A carriage neither in patients,nor in controls. In overall risk model, OR of VIE episode in FV Leiden/MTHFR C677T carrierswas 1.79 (95% CI 1.04-3.06; p = 0.05). This effect tended to be more pronounced in patients with idiopathic VTE (OR 2.32, 95% CI 1.05-5.08; p = 0.05). Total rate of FV Leiden and MTHFR C677T combinations was higher in patients with idiopathic VIE. Patients with VTE, particularly idiopathic, should be screened for FII G20210A, FV Leiden, MTHFR C677T, FVII R353Q G > A, and PAI-1 -675 5G/4G polymorphisms.